Launch of PacBio RS Platform Drives Pacific Biosciences' Q2 Revenues to $10.6M

The second quarter was marked by the commercial launch of the company's third-generation sequencing platform, and company officials said that it currently has a backlog of 35 systems, translating to $22 million in revenue still to be recognized.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories